Design, structure-activity relationships and in vivo characterization of 4-amino-3-benzimidazol-2-ylhydroquinolin-2-ones: a novel class of receptor tyrosine kinase inhibitors

J Med Chem. 2009 Jan 22;52(2):278-92. doi: 10.1021/jm800790t.

Paul A Renhowe ¹, Sabina Pecchi, Cynthia M Shafer, Timothy D Machajewski, Elisa M Jazan, Clarke Taylor, William Antonios-McCrea, Christopher M McBride, Kelly Frazier, Marion Wiesmann, Gena R Lapointe, Paul H Feucht, Robert L Warne, Carla C Heise, Daniel Menezes, Kimberly Aardalen, Helen Ye, Molly He, Vincent Le, Jayesh Vora, Johanna M Jansen, Mary Ellen Wernette-Hammond, Alex L Harris

Affiliations

Affiliation

1 Novartis Institutes for Biomedical Research, 4560 Horton Street, Emeryville, California 94608-2419, USA. [email protected]

PMID: 19113866 DOI: 10.1021/jm800790t

Abstract

The inhibition of key Receptor Tyrosine Kinases (RTKs) that are implicated in tumor vasculature formation and maintenance, as well as tumor progression and metastasis, has been a major focus in oncology research over the last several years. Many potent small molecule inhibitors of vascular endothelial growth factor receptor (VEGFR) and platelet-derived growth factor receptor (PDGFR) kinases have been evaluated. More recently, compounds that act through the complex inhibition of multiple kinase targets have been reported and may exhibit improved clinical efficacy. We report herein a series of potent, orally efficacious 4-amino-3-benzimidazol-2-ylhydroquinolin-2-one analogues as inhibitors of VEGF, PDGF, and Fibroblast Growth Factor (FGF) Receptor Tyrosine Kinases. Compounds in this class, such as 5 (TKI258), are reversible ATP-competitive inhibitors of VEGFR-2, FGFR-1, and PDGFRbeta with IC(50) values <0.1 microM. On the basis of its favorable in vitro and in vivo properties, compound 5 was selected for clinical evaluation and is currently in phase I clinical trials.

Name
Email *

	Sorry, but the email address you supplied was invalid.